JP2006506455A - ウイルス感染症の治療のための１−アシル−ピロリジン誘導体 - Google Patents
ウイルス感染症の治療のための１−アシル−ピロリジン誘導体 Download PDFInfo
- Publication number
- JP2006506455A JP2006506455A JP2005501534A JP2005501534A JP2006506455A JP 2006506455 A JP2006506455 A JP 2006506455A JP 2005501534 A JP2005501534 A JP 2005501534A JP 2005501534 A JP2005501534 A JP 2005501534A JP 2006506455 A JP2006506455 A JP 2006506455A
- Authority
- JP
- Japan
- Prior art keywords
- tert
- pyrrolidine
- butylbenzoyl
- methoxy
- isobutyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC(C)C[C@@](C[C@@](C[U]C)C1)(*1C(c1cc(OC)c(C(C)(C)C)cc1)=O)C(OC(C)(C)C)=O Chemical compound CC(C)C[C@@](C[C@@](C[U]C)C1)(*1C(c1cc(OC)c(C(C)(C)C)cc1)=O)C(OC(C)(C)C)=O 0.000 description 5
- GKKCTWFJWBMGID-UHFFFAOYSA-N CC(C)(C)c(ccc(C(C)=O)c1)c1OC Chemical compound CC(C)(C)c(ccc(C(C)=O)c1)c1OC GKKCTWFJWBMGID-UHFFFAOYSA-N 0.000 description 1
- OPCHAFVNDOZOBO-RQZCQDPDSA-N CC(C)CC(C(OC(C)(C)C)=O)/N=C/c1ncc(COC)[s]1 Chemical compound CC(C)CC(C(OC(C)(C)C)=O)/N=C/c1ncc(COC)[s]1 OPCHAFVNDOZOBO-RQZCQDPDSA-N 0.000 description 1
- COKUCCIHPJIDAE-QVWGJOIVSA-N CC(C)C[C@](CC(C1)C(C)C)(C(OC(C)(C)C)=O)N1C(c1ccc(C(C)(C)C)c(OC)c1)=O Chemical compound CC(C)C[C@](CC(C1)C(C)C)(C(OC(C)(C)C)=O)N1C(c1ccc(C(C)(C)C)c(OC)c1)=O COKUCCIHPJIDAE-QVWGJOIVSA-N 0.000 description 1
- BSBUQUPCVMXAIX-ZHCYEPILSA-N CCOC[C@@H](C[C@@]1(CC(C)C)C(O)=O)[C@H](c2ncc[s]2)N1C(c1cc(OC)c(C(C)(C)C)cc1)=O Chemical compound CCOC[C@@H](C[C@@]1(CC(C)C)C(O)=O)[C@H](c2ncc[s]2)N1C(c1cc(OC)c(C(C)(C)C)cc1)=O BSBUQUPCVMXAIX-ZHCYEPILSA-N 0.000 description 1
- ZOWPXBXFINYLBU-VDALTMKYSA-N CCOC[C@@H](C[C@@]1(CC(C)C)[IH](OC(C)(C)C)=O)[C@H](c2n[o]c(C)c2)N1C(c1cc(OC)c(C(C)(C)C)cc1)=O Chemical compound CCOC[C@@H](C[C@@]1(CC(C)C)[IH](OC(C)(C)C)=O)[C@H](c2n[o]c(C)c2)N1C(c1cc(OC)c(C(C)(C)C)cc1)=O ZOWPXBXFINYLBU-VDALTMKYSA-N 0.000 description 1
- ZUPJLZIMMUBGDT-UHFFFAOYSA-N COCc([s]1)cnc1Br Chemical compound COCc([s]1)cnc1Br ZUPJLZIMMUBGDT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0224774A GB0224774D0 (en) | 2002-10-24 | 2002-10-24 | Compounds |
| GB0229470A GB0229470D0 (en) | 2002-12-18 | 2002-12-18 | Compounds |
| GB0317141A GB0317141D0 (en) | 2003-07-22 | 2003-07-22 | Compounds |
| PCT/EP2003/011813 WO2004037818A1 (en) | 2002-10-24 | 2003-10-22 | 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006506455A true JP2006506455A (ja) | 2006-02-23 |
| JP2006506455A5 JP2006506455A5 (https=) | 2006-12-07 |
Family
ID=32180212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501534A Withdrawn JP2006506455A (ja) | 2002-10-24 | 2003-10-22 | ウイルス感染症の治療のための１−アシル−ピロリジン誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7304087B2 (https=) |
| EP (1) | EP1554274B1 (https=) |
| JP (1) | JP2006506455A (https=) |
| KR (1) | KR20050057670A (https=) |
| AR (1) | AR041816A1 (https=) |
| AT (1) | ATE418554T1 (https=) |
| AU (1) | AU2003276172A1 (https=) |
| BR (1) | BR0315417A (https=) |
| CA (1) | CA2503471A1 (https=) |
| CO (1) | CO5550450A2 (https=) |
| DE (1) | DE60325498D1 (https=) |
| IS (1) | IS7851A (https=) |
| MA (1) | MA27524A1 (https=) |
| MX (1) | MXPA05004435A (https=) |
| NO (1) | NO20052472L (https=) |
| PL (1) | PL376454A1 (https=) |
| TW (1) | TW200418848A (https=) |
| WO (1) | WO2004037818A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0304494D0 (en) * | 2003-02-27 | 2003-04-02 | Glaxo Group Ltd | Compounds |
| GB0408995D0 (en) * | 2004-04-22 | 2004-05-26 | Glaxo Group Ltd | Compounds |
| GB0423673D0 (en) * | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| GB0423672D0 (en) * | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| WO2006050035A1 (en) | 2004-10-29 | 2006-05-11 | Schering Corporation | Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents |
| GB0519488D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519478D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519485D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519486D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| JP2010520200A (ja) | 2007-02-28 | 2010-06-10 | クオナトウス ファーマシューティカルズ，インコーポレイテッド | 特定のマトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤を使用する肝疾患を治療する方法 |
| EP2142215B1 (en) | 2007-05-04 | 2012-03-07 | Vertex Pharmceuticals Incorporated | Combination therapy for the treatment of hcv infection |
| US20090053175A1 (en) * | 2007-08-24 | 2009-02-26 | Yat Sun Or | Substitute pyrrolidine derivatives |
| CN104710365A (zh) | 2008-04-28 | 2015-06-17 | 旭化成制药株式会社 | 苯丙酸衍生物及其用途 |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| BRPI0917013A2 (pt) | 2008-08-11 | 2016-02-16 | Glaxosmithkline Llc | métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto |
| BRPI0917458A2 (pt) | 2008-08-11 | 2015-12-01 | Glaxosmithkline Llc | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto |
| WO2011098451A1 (en) | 2010-02-10 | 2011-08-18 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| DK2534149T3 (da) | 2010-02-10 | 2015-01-05 | Glaxosmithkline Llc | 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat |
| US9340530B2 (en) | 2012-03-06 | 2016-05-17 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists |
| KR20160124157A (ko) | 2014-02-20 | 2016-10-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체 |
| MX2017006302A (es) | 2014-11-13 | 2018-02-16 | Glaxosmithkline Biologicals Sa | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| PT3440076T (pt) | 2016-04-07 | 2022-07-29 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas úteis como modeladores de proteína |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| US20220227761A1 (en) | 2019-05-16 | 2022-07-21 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
| WO2020232378A1 (en) | 2019-05-16 | 2020-11-19 | Silicon Swat, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| EP4077318B1 (en) | 2019-12-18 | 2025-10-15 | Ctxt Pty Ltd | Benzimidazole dimers as modulators of sting |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977075A (en) | 1995-04-21 | 1999-11-02 | Novartis Ag | N-aroylamino acid amides as endothelin inhibitors |
| AU1804299A (en) | 1997-12-08 | 1999-06-28 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| DE69938493T2 (de) | 1998-01-26 | 2009-05-20 | Massachusetts Institute Of Technology, Cambridge | Endoskop zur erfassung von fluoreszenzbilder |
| CN1328546A (zh) | 1998-04-23 | 2001-12-26 | 艾博特公司 | 作为神经氨酸酶抑制剂的吡咯烷 |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| EP1118287B1 (de) * | 2000-01-21 | 2004-11-24 | Alois Ing. Sampl | Steckbares Regalsystem |
| US6713502B2 (en) * | 2000-05-05 | 2004-03-30 | Smithkline Beecham Corporation | Anti-infectives |
| EP1339708A2 (en) | 2000-11-20 | 2003-09-03 | Scios Inc. | Indole-type inhibitors of p38 kinase |
| JP2005511574A (ja) | 2001-10-26 | 2005-04-28 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド |
| WO2003037893A1 (en) | 2001-11-02 | 2003-05-08 | Glaxo Group Limited | Acyl dihydro pyrrole derivatives as hcv inhibitors |
| AU2002335950A1 (en) | 2002-10-28 | 2004-05-13 | Marquage Antivol Sherlock, Inc. | Method of preventing theft of vehicles using intensive marking |
-
2003
- 2003-10-22 DE DE60325498T patent/DE60325498D1/de not_active Expired - Fee Related
- 2003-10-22 AT AT03809322T patent/ATE418554T1/de not_active IP Right Cessation
- 2003-10-22 MX MXPA05004435A patent/MXPA05004435A/es unknown
- 2003-10-22 AR ARP030103852A patent/AR041816A1/es not_active Application Discontinuation
- 2003-10-22 BR BR0315417-3A patent/BR0315417A/pt not_active IP Right Cessation
- 2003-10-22 AU AU2003276172A patent/AU2003276172A1/en not_active Abandoned
- 2003-10-22 WO PCT/EP2003/011813 patent/WO2004037818A1/en not_active Ceased
- 2003-10-22 US US10/531,884 patent/US7304087B2/en not_active Expired - Fee Related
- 2003-10-22 KR KR1020057006957A patent/KR20050057670A/ko not_active Withdrawn
- 2003-10-22 TW TW092129213A patent/TW200418848A/zh unknown
- 2003-10-22 PL PL03376454A patent/PL376454A1/xx not_active Application Discontinuation
- 2003-10-22 EP EP03809322A patent/EP1554274B1/en not_active Expired - Lifetime
- 2003-10-22 CA CA002503471A patent/CA2503471A1/en not_active Abandoned
- 2003-10-22 JP JP2005501534A patent/JP2006506455A/ja not_active Withdrawn
-
2005
- 2005-04-25 CO CO05038997A patent/CO5550450A2/es not_active Application Discontinuation
- 2005-05-06 MA MA28263A patent/MA27524A1/fr unknown
- 2005-05-19 IS IS7851A patent/IS7851A/is unknown
- 2005-05-23 NO NO20052472A patent/NO20052472L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20060258720A1 (en) | 2006-11-16 |
| AR041816A1 (es) | 2005-06-01 |
| ATE418554T1 (de) | 2009-01-15 |
| DE60325498D1 (de) | 2009-02-05 |
| EP1554274B1 (en) | 2008-12-24 |
| NO20052472L (no) | 2005-05-23 |
| MXPA05004435A (es) | 2005-07-26 |
| CO5550450A2 (es) | 2005-08-31 |
| US7304087B2 (en) | 2007-12-04 |
| KR20050057670A (ko) | 2005-06-16 |
| PL376454A1 (en) | 2005-12-27 |
| BR0315417A (pt) | 2005-08-16 |
| AU2003276172A1 (en) | 2004-05-13 |
| EP1554274A1 (en) | 2005-07-20 |
| WO2004037818A1 (en) | 2004-05-06 |
| TW200418848A (en) | 2004-10-01 |
| CA2503471A1 (en) | 2004-05-06 |
| IS7851A (is) | 2005-05-19 |
| MA27524A1 (fr) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7304087B2 (en) | 1-acyl-pyrrolidine derivatives for the treatment of viral infections | |
| US20050043545A1 (en) | 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors | |
| JP2005515172A (ja) | Ｈｃｖ阻害剤としての４−（６−員）−ヘテロアリールアシルピロリジン誘導体 | |
| US20070270475A1 (en) | 4-Methoxy-Pyrrolidine-2-Carboxylic Acid Compounds and Derivatives Thereof as Hepatitis C Virus Inhibitors | |
| US20050009873A1 (en) | Acyl dihydro pyrrole derivatives as hcv inhibitors | |
| WO2004096210A1 (en) | Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors | |
| JP2007533693A (ja) | Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体 | |
| WO2007039142A1 (en) | C (2) -heteroarylmethyl-c (4) -methoxymethyl acyl pyrrolidine compounds and their use for treating viral infections, especially hepatitis c virus | |
| WO2007039145A1 (en) | C (2) -heteroarylmethyl-c (4) -pyrazinyl-2-yl acyl pyrrolidine compounds and their use for treating viral infections, especially hepatitis c virus | |
| US20050176801A1 (en) | Acyl bicyclic derivatives of pyrrol | |
| US20090227600A1 (en) | 4-(pyrazine-2-yl) -pyrrolidine -2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors | |
| WO2004009543A2 (en) | 1-carbonyl-4-cyano-pyrrolidine-2-carboxylic acid derivatives as hepatitis c virus inhibitors | |
| WO2005079799A1 (en) | 4-acyl-piperazines as anti-viral agents | |
| WO2006100106A1 (en) | 3-carboxy pyrroles as anti-viral agents | |
| WO2004076415A1 (en) | 1- (hetero)aroyl-pyrrolidine-2-carboxylic acid derivatives useful as anti.viral agents | |
| WO2007039144A1 (en) | Pyrrolidine derivatives for treating viral infections | |
| WO2007039143A1 (en) | C (2) -heteroarylmethyl-c (4) -pyrazin-2-yl acyl pyrrolidine compounds and their user for treating viral infections, especially hepatitics c (hcv) | |
| ZA200502945B (en) | 1-Acyl-pyrrolidine derivatives for the treatment of viral infections. | |
| WO2004060889A1 (en) | 5-thiazole substituted 2-pyrrolidine-carboxylic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061023 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061023 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090428 |